Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dragonfly Therapeutics Inc.
Headquarters: Waltham, MA, United States of America
Website: https://www.dragonflytx.com/...
Year Founded: 2015
Status: Private
BioCentury | Jan 22, 2025
Politics, Policy & Law
Disclosures illuminate RFK Jr.’s ties to antivaccine litigation
HHS secretary nominee led group that spread debunked theories about vaccine safety, participated in lawsuits against vaccine, drug manufacturers
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Aug 7, 2024
Emerging Company Profile
Diagonal: Gluing receptor complexes back together
Newco uses AI/ML to find bispecific antibodies that can reassemble functional receptor complexes in the face of mutations
BioCentury | Aug 6, 2024
Management Tracks
A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
BioCentury | Jun 1, 2023
Management Tracks
Alkermes picks Loew to lead oncology spinout
Plus: Two new SVPs at Dragonfly, and updates from Abilita, OcuTerra and PineTree
BioCentury | Feb 14, 2023
Data Byte
The IL-12 clinical pipeline: about as many modalities as molecules
The companies casting wide net in attempt to harness IL-12’s immune stimulation without its toxicity
BioCentury | Feb 10, 2023
Deals
Feb. 9 Quick Takes: AbbVie’s Gonzalez says next deal could be ‘much larger’ than $2B
Plus: Full approval for Jemperli and updates from AZ, Regeneron, Prokarium and more
BioCentury | Feb 7, 2023
Product Development
Feb. 6 Quick Takes: Idorsia falls on Phase III miss
Plus: Arrowhead awaits J&J’s decision on HBV partnership and updates from Dragonfly, Sage-Biogen, IgGenix, Certa and more
BioCentury | Feb 2, 2023
Management Tracks
Mendila takes up CDO role at CureVac
Plus: BMS, Merck vet Eid joins Dragonfly and updates from Ariceum, AviadoBio, Poseida and more
BioCentury | May 3, 2022
Deals
Gilead’s $300M deal with Dragonfly builds on 2022’s NK cell momentum
Dragonfly attracts Gilead as fourth big biopharma partner
Items per page:
1 - 10 of 37